Shares of Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) rose 0.7% during trading on Monday . The company traded as high as $0.71 and last traded at $0.70. Approximately 72,337 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 406,223 shares. The stock had previously closed at $0.70.
Cue Biopharma Price Performance
The business has a 50 day moving average of $0.69 and a 200 day moving average of $0.96. The company has a market cap of $55.23 million, a PE ratio of -1.09 and a beta of 1.43.
Cue Biopharma (NASDAQ:CUE - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.03). The firm had revenue of $0.42 million during the quarter, compared to the consensus estimate of $0.90 million. Cue Biopharma had a negative return on equity of 228.43% and a negative net margin of 507.87%. Sell-side analysts forecast that Cue Biopharma, Inc. will post -0.76 EPS for the current fiscal year.
Hedge Funds Weigh In On Cue Biopharma
Institutional investors have recently added to or reduced their stakes in the company. Navalign LLC bought a new position in Cue Biopharma in the fourth quarter worth $27,000. Texas Capital Bank Wealth Management Services Inc bought a new position in shares of Cue Biopharma during the fourth quarter valued at $36,000. LPL Financial LLC increased its holdings in shares of Cue Biopharma by 139.5% during the fourth quarter. LPL Financial LLC now owns 42,929 shares of the company's stock valued at $47,000 after acquiring an additional 25,004 shares in the last quarter. XTX Topco Ltd increased its holdings in shares of Cue Biopharma by 69.8% during the fourth quarter. XTX Topco Ltd now owns 46,973 shares of the company's stock valued at $51,000 after acquiring an additional 19,308 shares in the last quarter. Finally, Jane Street Group LLC increased its holdings in shares of Cue Biopharma by 145.9% during the fourth quarter. Jane Street Group LLC now owns 63,767 shares of the company's stock valued at $70,000 after acquiring an additional 37,832 shares in the last quarter. Institutional investors own 35.04% of the company's stock.
About Cue Biopharma
(
Get Free Report)
Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.
Recommended Stories
Before you consider Cue Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cue Biopharma wasn't on the list.
While Cue Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
